Clinical Trial: DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623525) titled 'DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia' on May 19.

Brief Summary: This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT).

The study consists of three parts:

Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics.

Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks...